BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26780289)

  • 1. Hepatitis C reinfection after sustained virological response.
    Midgard H; Bjøro B; Mæland A; Konopski Z; Kileng H; Damås JK; Paulsen J; Heggelund L; Sandvei PK; Ringstad JO; Karlsen LN; Stene-Johansen K; Pettersson JH; Dorenberg DH; Dalgard O
    J Hepatol; 2016 May; 64(5):1020-1026. PubMed ID: 26780289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
    Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
    Pineda JA; Núñez-Torres R; Téllez F; Mancebo M; García F; Merchante N; Pérez-Pérez M; Neukam K; Macías J; Real LM;
    J Infect; 2015 Nov; 71(5):571-7. PubMed ID: 26212868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
    J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
    AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
    Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
    Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
    Weir A; McLeod A; Innes H; Valerio H; Aspinall EJ; Goldberg DJ; Barclay ST; Dillon JF; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Stanley AJ; Aitken C; Gunson R; Templeton K; Hunt A; McIntyre P; Hutchinson SJ
    Drug Alcohol Depend; 2016 Aug; 165():53-60. PubMed ID: 27268294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
    Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
    Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
    Marco A; Esteban JI; Solé C; da Silva A; Ortiz J; Roget M; Sarriera C; Teixidó N; Guerrero RA; Caylà JA
    J Hepatol; 2013 Jul; 59(1):45-51. PubMed ID: 23523577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
    Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV.
    Young J; Rossi C; Gill J; Walmsley S; Cooper C; Cox J; Martel-Laferriere V; Conway B; Pick N; Vachon ML; Klein MB;
    Clin Infect Dis; 2017 May; 64(9):1154-1162. PubMed ID: 28199495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway.
    Midgard H; Ulstein K; Backe Ø; Foshaug T; Sørli H; Vennesland K; Nilssen D; Dahl EH; Finbråten AK; Wüsthoff L; Dalgard O
    Int J Drug Policy; 2021 Oct; 96():103165. PubMed ID: 33642182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.
    Grady BP; Vanhommerig JW; Schinkel J; Weegink CJ; Bruisten SM; Lindenburg CE; Prins M
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1302-7. PubMed ID: 22825643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
    Grebely J; Pham ST; Matthews GV; Petoumenos K; Bull RA; Yeung B; Rawlinson W; Kaldor J; Lloyd A; Hellard M; Dore GJ; White PA;
    Hepatology; 2012 Apr; 55(4):1058-69. PubMed ID: 22031335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
    Askar S; Jelley R; McQue K; Allsop C; McCullough F; Miller C; Taha Y; Masson S; McPherson S
    J Viral Hepat; 2022 Aug; 29(8):685-690. PubMed ID: 35643915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinfection with hepatitis C virus following sustained virological response in injection drug users.
    Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1281-4. PubMed ID: 20594256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
    McDonald SA; Innes HA; Hayes PC; Dillon JF; Mills PR; Goldberg DJ; Barclay S; Allen S; Fox R; Fraser A; Kennedy N; Bhattacharyya D; Hutchinson SJ
    J Hepatol; 2015 Feb; 62(2):262-8. PubMed ID: 25195556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.